Terms: = Lung cancer AND PR, PGR, progesterone receptor AND Clinical Outcome
46 results:
1. Divergent tumor and immune cell reprogramming underlying immunotherapy response and immune-related adverse events in lung squamous cell carcinoma.
Chen M; Ma P; Zhang Y; Wang D; Yu Z; Fu Y; Zhao X; Wang M; Zhuang G; Jing Y
J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37857527
[TBL] [Abstract] [Full Text] [Related]
2. A non-inferiority randomized phase III trial of standard immunotherapy by checkpoint inhibitors vs. reduced dose intensity in responding patients with metastatic cancer: the MOIO protocol study.
Gravis G; Marino P; Olive D; Penault-LLorca F; Delord JP; Simon C; Lamrani-Ghaouti A; Sabatier R; Ciccolini J; Boher JM
BMC Cancer; 2023 May; 23(1):393. PubMed ID: 37131154
[TBL] [Abstract] [Full Text] [Related]
3. Positive
Huang S; Qi M; Tian T; Dai H; Tang Y; Huang R
Front Endocrinol (Lausanne); 2022; 13():959089. PubMed ID: 36407316
[TBL] [Abstract] [Full Text] [Related]
4. [Expression and prognostic value of programmed cell death ligand 1 in patients with locally advanced and non-EGFR-mutated non-small cell lung cancer receiving concurrent chemoradiotherapy].
Xue WJ; Bi N; Yang L; Wang X; Dong JY; Zhang T; Wu LF; Wang LH
Zhonghua Yi Xue Za Zhi; 2022 Feb; 102(6):406-411. PubMed ID: 35144339
[No Abstract] [Full Text] [Related]
5. C-reactive protein reduction post treatment is associated with improved survival in atezolizumab (anti-PD-L1) treated non-small cell lung cancer patients.
Patil NS; Zou W; Mocci S; Sandler A; Ballinger M; Flynn S; Kowanetz M; Hegde PS
PLoS One; 2021; 16(2):e0246486. PubMed ID: 33534859
[TBL] [Abstract] [Full Text] [Related]
6. Association Between Response to Nivolumab Treatment and Peripheral Blood Lymphocyte Subsets in Patients With Non-small Cell lung cancer.
Ottonello S; Genova C; Cossu I; Fontana V; Rijavec E; Rossi G; Biello F; Dal Bello MG; Tagliamento M; Alama A; Coco S; Boccardo S; Vanni I; Ferlazzo G; Moretta L; Grossi F; Mingari MC; Carrega P; Pietra G
Front Immunol; 2020; 11():125. PubMed ID: 32117275
[TBL] [Abstract] [Full Text] [Related]
7. Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy.
Bilen MA; Shabto JM; Martini DJ; Liu Y; Lewis C; Collins H; Akce M; Kissick H; Carthon BC; Shaib WL; Alese OB; Steuer CE; Wu C; Lawson DH; Kudchadkar R; Master VA; El-Rayes B; Ramalingam SS; Owonikoko TK; Harvey RD
BMC Cancer; 2019 Aug; 19(1):857. PubMed ID: 31464611
[TBL] [Abstract] [Full Text] [Related]
8. Crizotinib treatment for patients with EGFR mutation positive NSCLC that acquire cMET amplification after EGFR TKI therapy results in short-lived and heterogeneous responses.
van Veggel B; de Langen AJ; Hashemi S; Monkhorst K; Rosenberg EH; Heideman DAM; Radonic T; Smit EF
Lung Cancer; 2018 Oct; 124():130-134. PubMed ID: 30268451
[TBL] [Abstract] [Full Text] [Related]
9. The targeted inhibition of Hsp90 by a synthetic small molecule, DPide offers an effective treatment strategy against TNBCs.
Oh YJ; Park SY; Seo YH
Oncol Rep; 2018 Apr; 39(4):1775-1782. PubMed ID: 29436674
[TBL] [Abstract] [Full Text] [Related]
10. [The clinical characteristics of pulmonary benign metastasizing leiomyoma].
Wang HP; Shi JH; Zhang L
Zhonghua Nei Ke Za Zhi; 2017 Jul; 56(7):490-494. PubMed ID: 28693056
[No Abstract] [Full Text] [Related]
11. Volumetric Versus Unidimensional Measures of Metastatic Colorectal cancer in Assessing Disease Response.
Lubner MG; Stabo N; Lubner SJ; Del Rio AM; Song C; Pickhardt PJ
Clin Colorectal Cancer; 2017 Dec; 16(4):324-333.e1. PubMed ID: 28433601
[TBL] [Abstract] [Full Text] [Related]
12. Role of GSTP1 Ile105Val and XRCC1 Arg194Trp, Arg280His and Arg399Gln gene polymorphisms in the clinical outcome of advanced non-small cell lung cancer.
Zhao R; Chen G
Int J Clin Exp Pathol; 2015; 8(11):14909-16. PubMed ID: 26823821
[TBL] [Abstract] [Full Text] [Related]
13. Oxaliplatin-Based Chemotherapy in Advanced Neuroendocrine Tumors: clinical outcomes and Preliminary Correlation with Biological Factors.
Spada F; Antonuzzo L; Marconcini R; Radice D; Antonuzzo A; Ricci S; Di Costanzo F; Fontana A; Gelsomino F; Luppi G; Nobili E; Galdy S; Cella CA; Sonzogni A; Pisa E; Barberis M; Fazio N
Neuroendocrinology; 2016; 103(6):806-14. PubMed ID: 26789262
[TBL] [Abstract] [Full Text] [Related]
14. Association of GSTP1 and XRCC1 gene polymorphisms with clinical outcome of advanced non-small cell lung cancer patients with cisplatin-based chemotherapy.
Han B; Guo Z; Ma Y; Kang S; Wang Y; Wei Q; Wu X
Int J Clin Exp Pathol; 2015; 8(4):4113-9. PubMed ID: 26097600
[TBL] [Abstract] [Full Text] [Related]
15. Polymorphisms in ERCC1 and XPF gene and response to chemotherapy and overall survival of non-small cell lung cancer.
Shi ZH; Shi GY; Liu LG
Int J Clin Exp Pathol; 2015; 8(3):3132-7. PubMed ID: 26045829
[TBL] [Abstract] [Full Text] [Related]
16. clinical outcomes of CyberKnife stereotactic body radiotherapy for peripheral stage I non-small cell lung cancer.
Shen ZT; Wu XH; Li B; Zhu XX
Med Oncol; 2015 Mar; 32(3):55. PubMed ID: 25638468
[TBL] [Abstract] [Full Text] [Related]
17. Polymorphisms in ERCC1 gene could predict clinical outcome of platinum-based chemotherapy for non-small cell lung cancer patients.
Zhao X; Zhang Z; Yuan Y; Yuan X
Tumour Biol; 2014 Aug; 35(8):8335-41. PubMed ID: 24859833
[TBL] [Abstract] [Full Text] [Related]
18. [Clinicopathologic features and prognostic factors of malignant phyllodes tumors].
Jia C; Mei F; Zheng J; You JF; Liu JY
Zhonghua Bing Li Xue Za Zhi; 2013 Nov; 42(11):729-34. PubMed ID: 24447548
[TBL] [Abstract] [Full Text] [Related]
19. Preliminary experience of CyberKnife treatment of lung metastasis: the question about real clinical benefit.
Swangsilpa T; Yongvithisatid P; Pairat K; Dechsupa P; Dhanachai M; Dangprasert S; Narkwong L; Sitathanee C; Puataweepong P; Puddhikarant P; Jiarpinitnun C; Witoonpanich P; Ruangkanchanasetr R; Ukhumpun T; Khaophong J
J Med Assoc Thai; 2013 May; 96(5):603-13. PubMed ID: 23745317
[TBL] [Abstract] [Full Text] [Related]
20. Complete pathological response is predictive for clinical outcome after tri-modality therapy for carcinomas of the superior pulmonary sulcus.
Blaauwgeers JL; Kappers I; Klomp HM; Belderbos JS; Dijksman LM; Smit EF; Postmus PE; Paul MA; Oosterhuis JW; Hartemink KJ; Vos CG; Burgers JA; Dahele M; Phernambucq EC; Witte BI; Thunnissen E
Virchows Arch; 2013 May; 462(5):547-56. PubMed ID: 23549732
[TBL] [Abstract] [Full Text] [Related]
[Next]
